# **Kinetic and thermodynamic control of axial chirality in biaryl-derived fused oxazolidine lactams exploiting a centre-axis relay of unit efficiency**

**David J. Edwards,***<sup>a</sup>* **David House,***<sup>b</sup>* **Helen M. Sheldrake,***<sup>a</sup>* **Susan J. Stone***<sup>a</sup>* **and Timothy W. Wallace\****<sup>a</sup>*

*Received 27th April 2007, Accepted 18th June 2007 First published as an Advance Article on the web 3rd July 2007* **DOI: 10.1039/b706336a**

The condensation of a 2-substituted-2-aminoethanol with methyl 2 -formylbiphenyl-2-carboxylate produces only two of the four possible axially chiral 6,7-dihydrodibenz[*c*,*e*]oxazolo[3,2-*a*]azepin-9(4b*H*)-ones (fused oxazolidine lactams), with kinetically controlled diastereoisomer ratios of up to 96 : 4. Within each lactam product the central chirality of the oxazolidine-fused benzylic position C(4b) is relayed to the biaryl axis with unit efficiency, the mis-matching of these stereogenic elements being prohibited due to strain, as predicted by molecular mechanics calculations. Diastereoisomeric lactam pairs can be equilibrated by heating with acid, and under these thermodynamic conditions reversed diastereoisomer ratios of up to 26 : 74 are observed.

# **Introduction**

The control of axial chirality in biaryls has been a focus of much attention in recent years as these materials became prominent in synthetic, materials and supramolecular chemistry, and prompted the development of new methods for their enantioselective (atroposelective) synthesis.**<sup>1</sup>** The key component of chiral biaryls, a stereogenic axis, is also biologically significant, there being a large number of compounds whose physiological properties depend on their axial configuration. These include not only fixed-axis biaryls such as (a*R*)-gossypol, an oral anti-spermatogenic agent,**<sup>2</sup>** but also many flexible systems exemplified by *N*-acetylcolchinol methyl ether (NCME) **1**, an antimitotic agent whose (a*R*)-form binds strongly to tubulin<sup>3</sup> and whose  $(aR)$ - and  $(aS)$ -forms equilibrate in solution (ratio 3 : 1 in chloroform-*d*).**<sup>4</sup>** These properties of **1** serve to illustrate the phenomenon of dynamic axial chirality which, in appropriate circumstances, can be manipulated (*e.g.* inverted) to useful effect without breaking bonds.**<sup>5</sup>** The *sense* of the axial chirality in NCME **1** depends on the configuration of the benzylic stereocentre, where the acetamido substituent prefers a pseudo-equatorial orientation, and the three-atom bridge effectively operates as a mechanical centre-axis chirality relay. The *degree* of axial chirality in biaryls, *i.e.* the aryl–aryl dihedral angle, can also be controlled using suitable designs of multi-atom bridge.**6,7**

The interplay between benzylic central chirality and axis configuration, as illustrated above, is a recurrent theme in atroposelective biaryl synthesis,**<sup>1</sup>** and our interest in this area led us to investigate the potential of [7,5]-fused lactams based on 6,7 dihydrodibenz[*c*,*e*]oxazolo[3,2-*a*]azepin-9-one **2** as conformationally restrained biaryls. Although the ring system in **2** is analogous to the [5,5]- and [6,5]-fused lactams introduced and exploited so productively by Meyers and co-workers,**<sup>8</sup>** the biaryl lactams described in our preliminary publication**<sup>9</sup>** were the first of their



type. However, the heterocyclic nucleus was already known in the form of **3<sup>10</sup>** and **4**, **<sup>11</sup>** and another series of lactams based on **2** was subsequently described by Levacher and co-workers.**12,13** We report herein the details of our initial study, in which we identify complementary kinetic and thermodynamic routes to biaryl lactams of the form **2**, and from which we conclude that a chirality relay of unit efficiency links the biaryl axis and C(4b) in such systems.

# **Results and discussion**

The starting materials for our study were prepared from commercial diphenic anhydride **5** using the two sequences shown in Scheme 1. Heating the anhydride **5** with hydrazine hydrate gave the hydrazide **6**, **<sup>14</sup>** which could be cleaved to the acid-aldehyde **7** using periodic acid;**<sup>15</sup>** the ozonolysis of phenanthrene offers an alternative route to **7**. **<sup>16</sup>** The corresponding ester **9** was prepared by opening the anhydride **5** with methanol, followed by reduction to the known ester-alcohol **8** using borane-methyl sulfide.**<sup>17</sup>** The oxidation of **8** to **9** with manganese(IV) oxide has been described,**<sup>18</sup>** but in our hands this reaction sometimes gave significant amounts

*a School of Chemistry, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK. E-mail: tim.wallace@manchester.ac.uk; Fax: +44 (0) 161 275 4939*

*b Synthetic Chemistry, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK*



**Scheme 1** Preparation of biaryl starting materials **7** and **9**.

of the lactone **10**, a result which we ascribe to the variable activity of the manganese reagent. Fortunately the oxidation of **8** under Swern conditions**<sup>19</sup>** afforded the ester-aldehyde **9** cleanly and in good yield.

The polycyclic nucleus of **2** was first assembled by heating the acid-aldehyde **7** with (*S*)-valinol **11a** under dehydrating conditions, which gave a mixture of two products as indicated by <sup>1</sup>H NMR spectroscopy and TLC (Scheme 2 and Table 1). The characterising features of the NMR spectrum of the mixture were two singlets at  $\delta$  5.91 and 5.73 ppm, which were assigned to the respective H(4b) signals of the major and minor products (ratio  $> 5 : 1$ ). Chromatography afforded the crystalline lactams **12a** (84%) and

**Table 1** Condensation of the biaryls **7** and **9** with aminoalcohols **11**



**Scheme 2** Condensation of the biaryls **7** and **9** with aminoalcohols **11**.

**13a** (12%), which were identified as the respective (a*S*,4b*R*,7*S*) and (a*R*,4b*S*,7*S*) diastereoisomers by X-ray crystallography.**<sup>9</sup>** These lactams have highly twisted frameworks, with the aromatic rings of each biaryl unit 40–45*◦* from coplanarity and the respective carbonyls 36*◦* and 33*◦* out of the plane of the adjacent aromatic ring. The reactions of **7** with other commercial amino alcohols **11b–f** also gave two lactams **12** and **13**, each pair distinguishable through the characteristic H(4b) signals in their <sup>1</sup> H NMR spectra (Table 2 and Table 3), but the yields and diastereoselectivity of the process were at best moderate, leading to some isolation problems. The situation was improved using the ester-aldehyde **9**, whose condensation with valinol **11a** in toluene gave the lactam **12a** with a d.e. of 92% (entry 7). To shorten reaction times, other condensations of **9** were carried out under more forcing conditions (155 *◦*C, 3 d) which provided convenient access to the lactams **12** except in the case of *tert*-leucinol **11f** (entry 12). An alternative route to the phenylglycinol-derived lactam **12b** which proceeds at lower temperature, based on the activation of **7** with Mukaiyama's salt, was developed by the Levacher group.**<sup>13</sup>**

In principle, the condensation of **7** or **9** with an amino alcohol **11** could provide up to four diastereoisomeric lactams, and in order to rationalise the results in Table 1, in particular the absence of **14** and **15** from the product mixtures, the core structures **16** and **17** and the related systems **18–21** were analysed using molecular mechanics



*<sup>a</sup>* Method A: toluene, Dean–Stark, reflux, 36 h. Method B: xylene, bath temp. 155 *◦*C, 72 h. *<sup>b</sup>* Isolated yields after chromatography. *<sup>c</sup>* Estimated from the <sup>1</sup>H NMR spectrum of the product mixture. <sup>*d*</sup> Reflux maintained for 7 d. *<sup>e</sup>* Not obtained pure. <sup>*f*</sup> No products observed.

Table 2 <sup>1</sup>H NMR data  $(\delta$  values and multiplicity) for 'kinetic' lactams  $12^{\circ}$ **Table 2** 1H NMR data (*d* values and multiplicity) for 'kinetic' lactams **12***a*





techniques (Fig. 1). Minimum energy conformations were located for both **16** and **17** (Fig. 2), and the steric energy of **17** was calculated to exceed that of **16** by more than 100 kJ mol−<sup>1</sup> . This is a compelling difference, especially when considered in conjunction with the estimated 80 kJ mol<sup>-1</sup> by which the axial torsion barrier in a simple three-atom bridged biaryl can be raised by *o*,*o* dimethylation.**<sup>20</sup>** It can be concluded that the diastereoisomers **14** and **15** based on the mis-matched system **17** are effectively disallowed by strain, with major contributions from excessive bending and torsion (eclipsing). The structure **17** is also subject to a loss of amide resonance due to the pyramidalisation of the nitrogen,**<sup>21</sup>** which is manifested *inter alia* by the O(9)–C(9)–N(8)– C(7) dihedral angle (39.6*◦*) and the reduced sum of the bond angles at the nitrogen atom (352.6*◦*). Some insight into the uniqueness of the relationship between **16** and **17**, which feature a threeatom bridge containing two trigonal atoms, is provided by the analyses of **18–21**. In **18** and **19** the carbon atoms of the bridge are tetrahedral while the nitrogen is pyramidal, and the two structures would not appear to be differentiated on the basis of strain. However, in **20** and **21** the presence of one trigonal atom in the bridge is sufficient to bring about a matched/mis-matched centreaxis relationship in favour of **20**, based on steric strain. Examples of this relay are discussed later.

A proposed mechanism for the formation of the lactams **12** and **13** is shown in Scheme 3. The initial step is the formation of an imine species **22** which can equilibrate with the respective *trans*- and *cis*-oxazolidines **23** and **24**. In analogous systems such equilibria are dominated by the ring-opened forms  $(cf. 22)$ ,<sup>22</sup> but intermolecular *N*-acylation is kinetically selective for the *cis*-2,4 disubstituted oxazolidine form (*cf.* **24**) in which one face of the heterocyclic ring is unhindered.**<sup>23</sup>** In contrast, the intramolecular *N*-acylation which gives lactam **12** can proceed most favourably through the arrangement depicted in  $(aS)$ -23, in which the groups R and X are apart, whereas in the alternative (a*R*)-**24** leading to **13** these groups are close. The higher selectivity observed using the ester-aldehyde **9** and its failure to react with the bulky *tert*-leucinol **11f** (Table 1, entry 12) are consistent with this mechanistic picture.

A second series of molecular mechanics calculations was carried out on the lactams **12** and **13**, and the results (Table 4) indicate that the minor product **13** is the thermodynamically more stable isomer of each pair. On the basis of precedents**<sup>24</sup>** it was anticipated that the interconversion of **12** and **13** might be induced by treatment with acid, and the results of a study of this equilibration process are shown in Table 5.

**Table 4** Minimised steric energies*<sup>a</sup>* and equilibrium compositions for lactams **12** and **13**

	Minimised steric energies/ $kJ$ mol <sup>-1</sup>					
<b>Series</b>	12	13	$\Lambda$ G/kJ mol <sup>-1</sup>	Predicted ratio 12:13 at 25 °C		
a	127.624	124.729	2.894	23.7:76.3		
b	129.012	127.606	1.406	36.2:63.8		
$\mathbf c$	136.075	132.697	3.378	20.4:79.6		
d	108.918	107.626	1.292	37.3:62.7		
e	183.423	176.621	6.802	6.0:94.0		
f	146.698	142.445	4.253	15.2:84.8		

*<sup>a</sup>* Calculated using MacroModel 8.0 (MM3 force field).



**Fig. 1** Energy-minimised conformations of the fused dibenzazepines **16–21** and their steric energies, calculated using MacroModel 8.0 (MM3 force field).



**Fig. 2** Potential energy plots of the C(1)–C(13b)–C(13a)–C(13) biaryl dihedral angle (modulus) in lactams **16** and **17** in the region of their steric energy minima, calculated using MacroModel 8.0 (MM3 force field).

In an initial experiment (entry 1), the valinol-derived lactam **12a** in acetonitrile-*d*<sub>3</sub> was heated to 55 <sup>°</sup>C in the presence of a catalytic amount of *p*-toluenesulfonic acid, and the solution was monitored by <sup>1</sup> H NMR spectroscopy. The equilibration process was slow under these conditions, but the equilibration proceeded with the expected first-order kinetics (Fig. 3). The reaction was stopped after 33 d, after which time the ratio **12a**:**13a** was converging on a value of 1 : 2, thus confirming the greater thermodynamic stability of the diastereoisomer **13a** and that the overall lactam-forming sequence (Scheme 3) was kinetically controlled.

For convenience, many of the equilibrations shown in Table 5 were carried out at higher temperatures using an excess of trifluoroacetic acid (TFA), and two blanks (entries 3 and 6) confirmed the requirement for acid. It is noteworthy that in all cases the isomer distribution favoured the lactam **13**, as predicted by calculation. In some cases the calculated and observed isomer ratios were quite close, but the largest discrepancy (entry 10) serves as a reminder of the approximations made in assembling the results in Table 4: the steric energy-minimised structure of  $13e$  incorporated  $\pi$ -stacking between the benzyl and biaryl components that would be negated by aromatic solvents.

The mechanism for acid-induced equilibration is presumed to involve the protonation of the lactam **12** followed by ring-opening to the acyliminium species **26**, which can isomerise to **27** and recyclise to **28**, providing access to **13** (Scheme 4). The ratedetermining step is likely to be the ring-opening of **25**, in which the C(4b)–O(5) bond is fixed with poor alignment for elimination.

**Table 5** Acid-induced equilibration of the biaryl lactams **12** and **13**

Entry	Starting lactam R		Solvent		Added acid Temperature $T/\mathcal{C}^a$ Time/d Products			Observed ratio <sup>b</sup>	Calculated ratio $\epsilon$
	12a	Pr <sup>i</sup>	$MeCN-d$	$p$ -TsOH	55	33 <sup>d</sup>	$12a + 13a$ 36:64		26:74
	12a	Pr'	Toluene- $d_s$ p-TsOH		140		$12a + 13a$ 27:73		30:70
	12a	Pr <sup>i</sup>	Toluene- $d_{\rm s}$	None	140		12a		30:70
4	12a	Pr <sup>i</sup>	Toluene- $d_{s}$	CF <sub>3</sub> CO <sub>2</sub> H	100		$12a + 13a$	29:71	28:72
	12 <sub>b</sub>	Ph	Toluene- $d_8$	CF <sub>3</sub> CO <sub>2</sub> H	100		$12b + 13b$ 45:55		39:61
6	12 <sub>b</sub>	Ph	Xvlene	None	150		12b		40:60
	12c	Bn	Toluene- $d_{s}$	CF <sub>3</sub> CO <sub>2</sub> H	100		$12c + 13c$ 36:64		27:73
8	12c	<b>B</b> <sub>n</sub>	$HCO2$ H	None	100	3 <sup>d</sup>	$12c + 13c$	43:57	27:73
9	12d/13d <sup>e</sup>	Me	Toluene- $d_{\rm s}$	CF <sub>3</sub> CO <sub>2</sub> H	100		$12d + 13d$	34:66	40:60
10	$12e/13e^{f}$	CH,OBn	Xvlene	CF <sub>3</sub> CO <sub>2</sub> H	150		$12e + 13e$	30:70	13:87
11	12f/13f <sup>g</sup>	Bu'	Toluene	CF <sub>3</sub> CO <sub>2</sub> H	100		$12f + 13f$	26:74	21:79

*<sup>a</sup>* Bath temperature. *<sup>b</sup>* Estimated from the <sup>1</sup> H NMR spectrum of the product mixture. *<sup>c</sup>* Predicted equilibrium composition at *T ◦*C based on calculated steric energies (Table 4). *<sup>d</sup>* Stopped before completion. *<sup>e</sup>* Starting ratio 56 : 44. *<sup>f</sup>* Starting ratio 50 : 50. *<sup>g</sup>* Starting ratio 64 : 36.



**Scheme 3** Proposed mechanism for the formation of **12** and **13**.





**Scheme 4** Proposed mechanism for the acid-catalysed equilibration of **12** and **13**.

**Fig. 3** The progress of the equilibration of lactams  $12a$  and  $13a$  in CD<sub>3</sub>CN at 55 *◦*C. The fitted curve for [**12a**] corresponds to an observed rate constant  $(k_1 + k_{-1})$  of  $1.1 \times 10^{-6}$  s<sup>-1</sup> and an equilibrium ratio of 1 : 2.

This can be seen in the crystal structure of **12a**, in which the dihedral angles  $C(4) - C(4a) - C(4b) - O(5)$  and  $C(9) - N(8) - C(4b) -$ O(5) are 3.7*◦* and 177.2*◦* respectively, *i.e.* the oxazolidine C–O bond is essentially orthogonal to both the aromatic and amide  $\pi$ -systems (Fig. 4). The protonated oxygen therefore receives little assistance from either when operating as a leaving group. The isomer **13a** is similarly situated, the corresponding dihedral angles being 2.0*◦* and 165.4*◦*.



**Fig. 4** Dihedral angles affecting O(5) from the X-ray crystal structure of **12a**. **9**

The results of this study confirm that a mobile biaryl axis can be restrained in a predictable and fixed configuration by incorporation within a fused oxazolidine lactam of the type developed and used extensively in synthesis by Meyers *et al.***<sup>8</sup>** The most prominent feature of such lactams, illustrated by the properties of **12a–f** and **13a–f**, is the effectiveness of the mechanical link between the benzylic position C(4b) and the biaryl axis, through which stereochemical information is relayed with complete fidelity. Related chirality relays are present in the chemical literature, one such example being the cyclisation of the iminium species **29** which, on the basis of analogy with **20**/**21**, presumably gave  $(\pm)$ -30, although this was not specified.<sup>25</sup> Other reactions of this type were reported by Hilt *et al.*, **<sup>26</sup>** who confirmed the cyclisation of  $(\pm)$ -31 to  $(\pm)$ -32 using X-ray crystallography. Only one other, non-crystalline, diastereoisomer was isolated from this reaction (d.r. 8 : 1) but its configuration remained unspecified. Again, by analogy with **20**/**21** the minor diastereoisomer was probably  $(\pm)$ -33, as the alternative axis-centre permutation would be disfavoured due to strain.



The most intriguing illustration of benzylic centre-axis complementarity is the observation by Zavada and co-workers that the zinc bromide-induced elimination of cyanide ion from the fixedaxis biaryl **34** produces only **35**, indicating that only the axial cyano group is expelled.**<sup>27</sup>** Moreover, the reverse reaction, in which **35** undergoes the addition of cyanide ion, is also completely selective, regenerating **34** in the absence of stereoisomers. The centre-axis stereochemical relay thus operates in both directions, with the configuration of the axis dictating the orbital alignment of the imine moiety in **35**.

### **Conclusions**

The formation of biaryl-fused lactams **12** *via* the mechanism shown in Scheme 3 amounts to the dynamic kinetic resolution of **7** or **9**, whose flexible biaryl axis is converged to a single configuration in the form of the derived lactam **12**. The overall sequence involves the relay of chirality from the auxiliary amino alcohol **11** to the benzylic fusion position, C(4b), which proceeds with kinetic selectivity (up to 92% d.e.) originating in the faster cyclisation of (a*S*)-**23** as compared to (a*R*)-**24**. The alternative cyclisations of **23** through an (*R*)-configured axis to give **14**, and of **24** through an (*S*)-configured axis to give **15**, are prohibited by strain, which is manifested in the lactams **12** and **13** as a chirality relay of unit efficiency between C(4b) and the biaryl axis. The diastereoisomeric pairs in each lactam series can be interconverted by heating with acid, leading to equilibrium mixtures in which **13** generally predominates by *ca.* 3 : 1.

Given the established advantages of amino alcohols as chiral auxiliaries, based on their ready availability in enantiopure form and the methods by which they can be installed, exploited and disconnected,**<sup>8</sup>** biaryl-fused oxazolidine lactams of the forms **12**

# **Experimental**

Melting points were determined using a Kofler hot-stage or an Electrothermal apparatus and are uncorrected. IR spectra were recorded for neat thin films on NaCl plates, using Perkin-Elmer 1710FT or Nicolet Nexus 670/870 spectrometers. NMR spectra were measured on Bruker DPX200, AC300 and Advance 400 instruments for solutions in deuteriochloroform, unless otherwise indicated; resonances were assigned with the aid of COSY, HMBC, HMQC and DEPT spectra where appropriate. Low-resolution mass spectra were measured on a Micromass LCT instrument using a Waters 2790 separations module with electrospray (ES+) ionisation and TOF fragment detection. High-resolution mass spectra were recorded on ThermoFinnigan MAT95XP or Kratos Concept S1 instruments. Data for most of the peaks of intensity <20% of that of the base peak are omitted. Elemental analyses were carried out by the UMIST and University of Manchester microanalytical services. Optical rotations were measured at 589 nm using an AA-100 polarimeter (Optical Activity Ltd). The sealed tubes used in equilibration experiments were screw-capped and made from thick-walled glass (Aldrich Z18106-4).

Starting materials and solvents were routinely purified by conventional techniques**<sup>28</sup>** and most reactions were carried out under nitrogen or argon. Organic solutions were dried using anhydrous magnesium sulfate and concentrated by rotary evaporation. Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 60 on aluminium plates containing a 254 nm fluorescent indicator. The chromatograms were visualised by the use of UV light or the following developing agents: ethanolic vanillin or potassium permanganate. Unless otherwise indicated, preparative (column) chromatography was carried out using the flash technique**<sup>29</sup>** on 60H silica gel (Merck 9385). Compositions of solvent mixtures are quoted as ratios of volume. 'Petroleum' refers to a light petroleum fraction, b.p. 40–60 *◦*C, unless otherwise stated. 'Ether' refers to diethyl ether. 'Xylene' refers to anhydrous *o*-xylene (Aldrich 294780).

#### **2 -(Hydrazinocarbonyl)biphenyl-2-carboxylic acid 6<sup>14</sup>**

To a solution of hydrazine monohydrate (4.0 mL, 82.5 mmol) in water (4 mL) at 0 *◦*C was added diphenic anhydride **5** (8.00 g, 35.7 mmol) over a period of 5 min with vigorous stirring and then the mixture was heated to 90 *◦*C for 1 h. The reaction was cooled and poured into water (50 mL). The solution was acidified with conc. HCl to pH 2 with vigorous stirring until a gummy brown solid began to form. Chilling and scratching gave a fine white precipitate. Filtration and crystallisation (EtOH) gave the monohydrazide **6** (8.70 g, 95%) as a colourless solid, m.p. 182.5– 183 <sup>°</sup>C (Found: C, 65.4; H, 5.0; N, 10.6. C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> requires C, 65.62; H, 4.72; N, 10.93%); *m*max/cm−<sup>1</sup> 3269, 3165; *d*<sup>H</sup> (300 MHz, CDCl3) 7.76 (1 H, dd, *J* 1.5, 7.5 Hz, ArH), 7.52–7.38 (5 H, m, ArH), 7.14–7.09 (3 H, m, ArH); δ<sub>c</sub> (100 MHz, CDCl<sub>3</sub>) 127.4,

127.6, 129.3, 129.6, 130.3, 130.6, 130.9, 132.3, 134.3, 140.4, 140.9, 168.2, 169.1; *m*/*z* 279 ([M + Na]+ , 25%), 257 ([M + H]+, 18), 239 (100);  $R_f$  0.20 (EtOAc–EtOH, 3 : 2).

# **2 -Formylbiphenyl-2-carboxylic acid 7<sup>15</sup>**

To a cooled solution (0 <sup>°</sup>C) of periodic acid (as H<sub>5</sub>IO<sub>6</sub>, 1.54 g, 6.8 mmol) in water (36 mL) and aq. ammonium hydroxide (8% w/w, 14 mL) was added the hydrazide **6** (1.0 g, 3.9 mmol) dissolved in aq. ammonium hydroxide (8% w/w, 7 mL) with vigorous stirring, keeping the temperature below 5 *◦*C. The mixture was stirred at 5 *◦*C for 5 min and then at room temperature for 15 min. Conc. sulfuric acid (*ca.* 6 mL) was added, producing a gummy brown solid, which was dissolved in dichloromethane (30 mL). The layers were separated, the aqueous layer was extracted with dichloromethane ( $3 \times 30$  mL), and the combined organic phase was dried over MgSO<sub>4</sub> and evaporated. Chromatography of the residual brown oil (80 g SiO<sub>2</sub>, EtOAc–dichloromethane 1 : 4) and crystallisation from EtOAc gave the title compound **7** (440 mg, 50%) as a white solid, m.p. 134–136 *◦*C [lit.**<sup>16</sup>** 134–135 *◦*C (MeOH– water)] (Found: C, 74.1; H, 4.6. C<sub>14</sub>H<sub>10</sub>O<sub>3</sub> requires C, 74.33; H, 4.46%); *m*max/cm−<sup>1</sup> 3064, 2843, 1728, 1689, 1596, 1402, 1274, 1200, 757;  $\delta$ <sub>H</sub> (300 MHz, CDCl<sub>3</sub>) 10.30 (1 H, s, OH), 9.78 (1 H, s, CHO), 8.11 (1 H, dd, *J* 1.4, 7.9 Hz, ArH), 7.99 (1 H, dd, *J* 1.5, 7.5 Hz, ArH), 7.62–7.48 (4 H, m, ArH), 7.30 (1 H, dd, *J* 1.2, 7.5 Hz, ArH), 7.23 (1 H, dd, *J* 1.1, 7.5 Hz, ArH);  $\delta_c$  (75 MHz, CDCl<sub>3</sub>) 128.0, 128.3, 128.6, 129.6, 130.4, 131.5, 132.3, 132.7, 133.6, 134.1, 140.6, 145.2, 172.2, 192.1;  $m/z$  290 ( $[M + 2Na + H<sub>2</sub>O]$ <sup>+</sup>, 100%), 249 ( $[M +$ Na]<sup>+</sup>, 30), 209 (6), 181 (50); *R*<sub>f</sub> 0.20 (EtOAc-dichloromethane,  $1:4$ ).

# **Methyl 2 -hydroxymethylbiphenyl-2-carboxylate 8**

A stirred suspension of diphenic anhydride **5** (3.52 g, 15.7 mmol) in MeOH (50 mL) was heated to reflux for 3.3 h. The resulting solution was concentrated *in vacuo* to yield a dark oil. To a stirred solution of this oil in THF (100 mL) at 0 *◦*C was added dropwise a solution of borane–dimethylsulfide in THF (2 M, 14.1 mL, 28.2 mmol) and the resulting solution was allowed to warm to room temperature over 23.5 h. The mixture was cautiously quenched with MeOH (10 mL) and the volatiles removed *in vacuo*. The residue was diluted with EtOAc (100 mL) and washed with saturated aqueous NaHCO<sub>3</sub> ( $2 \times 50$  mL). The organic phase was dried, filtered, concentrated *in vacuo* and purified by chromatography (EtOAc–hexane, 1 : 3), which gave the title compound **8** (2.56 g, 67% over two steps) as a colourless oil;  $\delta_H$ (300 MHz, CDCl3) 7.94 (1 H, dd, *J* 0.8, 7.5 Hz, 6-H), 7.58–7.22 (6 H, m, ArH), 7.06 (1 H, d, *J* 6.8 Hz, 3 -H), 4.44 (1 H, d, *J* 12.1 Hz, C*H*H OH), 4.38 (1 H, d, *J* 12.1 Hz, CH*H* OH), 3.67 (3 H, s, OCH<sub>3</sub>), 1.94 (1 H, s, OH) (in accord with published data<sup>17</sup>);  $R_f$ 0.23 (EtOAc–hexane, 3 : 7).

### **Methyl 2 -formylbiphenyl-2-carboxylate 9**

**Method A (ref. 18).** To a stirred solution of the ester-alcohol **8** (2.56 g, 10.6 mmol) in dichloromethane (200 mL) was added  $MnO<sub>2</sub>$  (80% pure; 10.82 g, 0.10 mol) and the resulting suspension was heated under reflux for 3 h. The reaction mixture was cooled to room temperature, filtered through Celite and concentrated *in vacuo* to yield a mixture (*ca.* 1 : 1) of **9** and **10** (2.36 g) as a colourless oil. Chromatography (EtOAc–hexane, 15 : 85) gave a sample of the ester-aldehyde 9 (484 mg, 19%) as a colourless oil;  $\delta_{\rm H}$  (300 MHz, CDCl3) 9.81 (1 H, s, CHO), 8.06 (1 H, d, *J* 7.0 Hz, ArH), 8.02 (1 H, d, *J* 7.9 Hz, ArH), 7.64–7.50 (4 H, m, ArH), 7.30 (1 H, d, *J* 7.5 Hz, ArH), 7.26 (1 H, d, *J* 8.7 Hz, ArH), 3.63 (3 H, s, OMe);  $v_{\text{max}}$ /cm<sup>-1</sup> 3062, 2951, 2842, 2751, 1728, 1696, 1596, 1435, 1258, 1196, 1129, 1086, 761, 668; *R<sub>f</sub>* 0.52 (EtOAc–hexane, 3 : 7). Further elution of the column yielded a mixed fraction (1.45 g, 61%) followed by 7*H*dibenzo[*c*,*e*]oxepin-5-one **10** (425 mg, 19%) as white crystals, m.p. 132–135 °С [lit.<sup>30</sup> 132–134 °С (sublimed)]; ∂<sub>Н</sub> (300 МНz, CDCl<sub>3</sub>) 7.98 (1 H, d, *J* 7.9 Hz, ArH), 7.70–7.40 (7 H, m, Ar*H*), 5.03 (2 H, br d, *J* 15.5 Hz, 7-H<sub>2</sub>) (in accord with published data<sup>31</sup>);  $v_{\text{max}}/cm^{-1}$ 3069, 1716 (C=O), 1600, 1449, 1379, 1277, 1226, 1111, 1091, 1048, 1011, 765, 740; *R*<sup>f</sup> 0.42 (EtOAc–hexane, 3 : 7).

**Method B.** A solution of DMSO (0.51 mL, 561 mg, 7.2 mmol, 1.3 eq.) in dichloromethane (3 mL) was added to a 2 M solution of oxalyl dichloride (3 mL, 6.0 mmol) in dichloromethane (20 mL) at −78 *◦*C and stirred for 30 min. The ester-alcohol **8** (1.33 g, 5.5 mmol) in dichloromethane (5 mL) was added and the reaction mixture stirred for a further 30 min at −78 *◦*C. Triethylamine (2 mL, 1.45 g, 14.3 mmol) was added and the reaction mixture was allowed to warm to room temperature while stirring for 3 h. The mixture was quenched with aq. ammonium chloride (2 M, 20 mL), extracted with dichloromethane ( $3 \times 30$  ml), dried (Na2SO4) and concentrated, giving the ester-aldehyde **9** as a pale yellow oil (1.20 g, 91%), identical (TLC, <sup>1</sup>H NMR) to material obtained using Method A above.

## **Formation of biaryl lactams (Table 1)**

**Method A.** From the acid-aldehyde **7** in toluene: A solution of 2 -formylbiphenyl-2-carboxylic acid **7** and the appropriate aminoalcohol **11** (1.4–1.5 mol. equiv.) in toluene was heated under reflux in a Dean–Stark apparatus for 36 h. The solution was cooled, evaporated *in vacuo* and the residue was analysed by <sup>1</sup>H NMR spectroscopy to determine the diastereoisomer ratio (see Table 2 and Table 3 for <sup>1</sup>H NMR data). The products were isolated by chromatography over silica gel.

**Method B.** From the ester-aldehyde **9** in xylene: A solution of methyl 2 -formylbiphenyl-2-carboxylate **9** and the appropriate aminoalcohol **11** (1.4–1.5 mol. equiv.) in xylene was heated at 155 *◦*C (bath temp.) for 3 d. The solution was cooled, evaporated in vacuo and the residue was analysed by <sup>1</sup>H NMR spectroscopy to determine the diastereoisomer ratio. The products were isolated by chromatography over silica gel.

### **(a***S***,4b***R***,7***S***)-6,7-Dihydro-7-isopropyldibenz[***c***,***e***]oxazolo[3,2** *a***]azepin-9(4b***H***)-one 12a and (a***R***,4b***S***,7***S***)-6,7-dihydro-7 isopropyldibenz[***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 13a**

**Method A.** The acid-aldehyde **7** (280 mg, 1.24 mmol) and (*S*) valinol **11a** (180 mg, 1.74 mmol) in toluene (16 mL) was heated under reflux in a Dean–Stark apparatus under Ar for 36 h. TLC indicated complete conversion, the reaction was cooled and the solvent removed *in vacuo*. The residue was partially purified by chromatography over silica gel (80 g  $SiO<sub>2</sub>$ , EtOAc–hexane 1 : 5 as eluant), which gave the *title compound* **12a** (210 mg, 58%) as colourless crystals, m.p. 121–123 *◦*C (EtOAc) (Found: C, 77.7; H,

6.8; N, 5.0.  $C_{19}H_{19}NO_2$  requires C, 77.79; H, 6.53; N, 4.77%);  $[a]_D^{23}$ −183 ± 7 (*c* 1.9, CHCl<sub>3</sub>);  $v_{\text{max}}$ /cm<sup>-1</sup> 3068, 2959, 2885, 1639, 1600, 1449, 1406, 1289, 1216, 1173, 1080, 854;  $\delta_c$  (75 MHz, CDCl<sub>3</sub>) 16.5 (Me<sub>A</sub>), 19.8 (Me<sub>B</sub>), 28.0 (*CHMe<sub>2</sub>*), 61.9 (7-C), 67.2 (6-C), 86.6 (4b-C), 122.3, 128.4 (two), 129.2, 129.4, 130.0, 130.2 and 131.4 (Ar*C*H), 135.7, 136.2, 136.6 and 139.0 (quaternary Ar*C*), 164.5 (8-C); *m*/*z* 609 ([2M + Na]+, 100%), 357 (79), 294 ([M + H]+, 82);  $R_f$  0.30 (EtOAc–hexane, 1 : 4). Mixed fractions were condensed to give an oil (139 mg, 38%) which was purified by preparative TLC  $[20 \times 20 \times 0.02 \text{ cm}$  (Merck 1.05583); multiple elution with EtOAc– hexane 1 : 6], giving **12a** (95 mg, 26%) and the *title compound* **13a** (42 mg, 11.5%), m.p. 114–115 *◦*C (petroleum, b.p. 60–80 *◦*C) (Found: C, 78.0; H, 6.8; N, 5.0. C<sub>19</sub>H<sub>19</sub>NO<sub>2</sub> requires C, 77.79; H, 6.53; N, 4.77%);  $[a]_D^{27}$  +148  $\pm$  5 (*c* 2.25, CHCl<sub>3</sub>);  $v_{\text{max}}$ /cm<sup>-1</sup> 3064, 2959, 2874, 1639, 1596, 1445, 1402, 1344, 1169, 1080, 994, 963, 858, 742, 703;  $\delta_c$  (75 MHz, CDCl<sub>3</sub>) 18.7 (Me), 19.7 (Me), 30.7 (*CHMe<sub>2</sub>*), 63.0 (7-C), 69.5 (6-C), 86.1 (4b-C), 122.5, 128.3, 128.4, 129.1, 129.7, 130.3, 130.7 and 131.8 (Ar*C*H), 134.1, 136.2, 137.6 and 139.3 (quaternary Ar*C*), 165.4 (8-C); *m*/*z* 609 ([2M + Na]+, 100%), 357 (88), 294 ([M + H]<sup>+</sup>, 81); *R<sub>f</sub>* 0.28 (EtOAc–hexane,  $1:4$ .

**From ester 9.** Heating the ester-aldehyde **9** (230 mg, 0.96 mmol) and (*S*)-valinol **11a** (148 mg, 1.43 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 7 d gave the mixed lactams **12a** and **13a** (total 200 mg, 71%, ratio 96 : 4).

# **(a***S***,4b***R***,7***S***)-6,7-Dihydro-7-phenyldibenz[***c***,***e***]oxazolo[3,2** *a***]azepin-9(4b***H***)-one 12b and (a***R***,4b***S***,7***S***)-6,7-dihydro-7 phenyldibenz[***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 13b**

**Method A.** Heating the acid-aldehyde **7** (296 mg, 1.31 mmol) and the amino alcohol **11b** (270 mg, 1.97 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 36 h gave the mixed lactams **12b** and **13b** (total 320 mg, 75%, ratio 70 : 30).

**Method B.** Heating the ester-aldehyde **9** (100 mg, 0.42 mmol) and (*S*)-phenylglycinol **11b** (86 mg, 0.63 mmol) in xylene (5 mL) at 155 *◦*C (bath temp.) for 3 d followed by removal of the solvent *in vacuo* gave a mixture of isomeric lactams (ratio 91 : 9). Chromatography (EtOAc–hexane, 1 : 4) gave the *title compound* **12b** (120 mg, 88%) as colourless needles, m.p. 143–145 *◦*C (MeOH) (lit.**<sup>13</sup>** 138–140 *◦*C); [*a*] 28 <sup>D</sup> −86 ± 8 (*c* 0.26, CHCl3); *m*max/cm−<sup>1</sup> 3662, 3471, 3269, 3067, 3021, 2948, 2889, 1638, 1452, 1398, 1339, 1277, 1211, 1157, 904, 737;  $\delta_c$  (100 MHz, CDCl<sub>3</sub>) 60.2 (6-C), 74.0 (7-C), 86.6 (4b-C), 121.8, 126.3 (two), 127.8, 128.2 (two), 128.8 (two), 129.1, 129.4, 130.0, 130.2 and 131.4 (Ar*C*H), 134.8, 136.2, 136.4, 138.3 and 140.8 (quaternary Ar*C*), 163.7 (8-C); *m*/*z* 677 ([2M + Na]<sup>+</sup>, 49), 510 (53), 391 ([M + 2Na + H<sub>2</sub>O]<sup>+</sup>, 58), 355 (100), 350 ([M + Na]+, 82), 329 (76), 235 (73), 207 (38) (Found: M + Na, 350.1145; C<sub>22</sub>H<sub>17</sub>O<sub>2</sub>NNa requires 350.1152); *R<sub>f</sub>* 0.25 (EtOAc– hexane, 3 : 7).

#### **(a***S***,4b***R***,7***S***)-6,7-Dihydro-7-(phenylmethyl)dibenz[***c***,***e***]oxazolo[3,2** *a***]azepin-9(4b***H***)-one 12c and (a***R***,4b***S***,7***S***)-6,7-dihydro-7- (phenylmethyl)dibenz[***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 13c**

**Method A.** Heating the acid-aldehyde **7** (260 mg, 1.15 mmol) and (*S*)-phenylalaninol **11c** (260 mg, 1.72 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 36 h gave the mixed

lactams **12c** and **13c** (total 210 mg, 54%), ratio 62 : 38 by <sup>1</sup> H NMR spectroscopy.

**Method B.** Heating the ester-aldehyde **9** (110 mg, 0.46 mmol) and (*S*)-phenylalaninol **11c** (104 mg, 0.69 mmol) in xylene (5 mL) at 155 *◦*C (bath temp.) for 3 d followed by removal of the solvent *in vacuo* gave a mixture of isomeric lactams (ratio 92 : 8). Chromatography (EtOAc–hexane, 15 : 85) gave the *title compound* **12c** (129 mg, 83%) as a colourless solid, m.p. 84– 84.5 *◦*C (dichloromethane) (Found: C, 80.75; H, 5.67; N, 4.03.  $C_{23}H_{19}NO_2$  requires C, 80.92; H, 5.61; N, 4.10%);  $[a]_D^{26} - 226 \pm 9$  $(c$  1.0, CHCl<sub>3</sub>); *v*<sub>max</sub>/cm<sup>-1</sup> 3069, 2927, 1638, 1447, 1406, 750; δ<sub>c</sub> (100 MHz, CDCl3) 37.0 (Ph*C*H2), 58.2 (7-C), 69.4 (6-C), 86.0 (4b-C), 121.7, 126.7, 128.13, 128.15, 128.7 (two), 128.9, 129.4, 129.6 (two), 129.9, 130.0 and 131.3 (Ar*C*H), 134.8, 136.1, 136.2, 137.9 and 138.4 (quaternary Ar*C*), 163.9 (8-C); *m*/*z* 705 ([2M + Na]+,  $46\%$ ),  $405$  ([M + 2Na + H<sub>2</sub>O]<sup>+</sup>, 69), 364 ([M + Na]<sup>+</sup>, 100), 342 ([M + H]<sup>+</sup>, 82) (Found: M, 341.1416; C<sub>23</sub>H<sub>19</sub>O<sub>2</sub>N requires 341.1410); R<sub>f</sub> 0.38 (EtOAc–hexane, 3 : 7). Further elution of the column yielded a mixed fraction (11 mg, 7%) and the *title compound* **13c** (9 mg, 6%) as a colourless oil;  $v_{\text{max}}/cm^{-1}$  2913, 2844, 1642, 1448, 1081;  $\delta_c$  (100 MHz, CDCl<sub>3</sub>) 38.5 (*C*H<sub>2</sub>Ph), 58.5 (7-C), 70.5 (6-C), 85.8 (4b-C), 121.9, 126.7, 128.2, 128.4, 128.7 (two), 128.9, 129.5 (two), 129.6, 129.8, 130.2 and 131.5 (Ar*C*H), 133.9, 135.9, 137.2, 137.8 and 139.4 (quaternary Ar*C*), 164.2 (8-C); *m*/*z* 705 ([2M + Na]+,  $11\%$ ), 405 ([M + 2Na + H<sub>2</sub>O]<sup>+</sup>, 47), 364 ([M + Na]<sup>+</sup>, 96), 342 ([M + H<sup> $+$ </sup>, 100) (Found: M, 341.1412;  $C_{23}H_{19}O_2N$  requires 341.1410);  $R_f$ 0.31 (EtOAc–hexane, 3 : 7).

# **(a***S***,4b***R***,7***S***)-6,7-Dihydro-7-methyldibenz[***c***,***e***]oxazolo[3,2** *a***]azepin-9(4b***H***)-one 12d and (a***R***,4b***S***,7***S***)-6,7-dihydro-7 methyldibenz[***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 13d**

**Method A.** Heating the acid-aldehyde **7** (290 mg, 1.28 mmol) and (*S*)-2-amino-1-propanol **11d** (144 mg, 1.92 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 36 h gave the mixed lactams **12d** and **13d** (total 200 mg, 59%), ratio 56 : 44 by <sup>1</sup>H NMR spectroscopy.

**Method B.** Heating the ester-aldehyde **9** (95 mg, 0.40 mmol) and (*S*)-2-amino-1-propanol **11d** (45 mg, 0.60 mmol) in xylene (5 mL) at 155 *◦*C (bath temp.) for 3 d followed by removal of the solvent *in vacuo* gave a mixture of isomeric lactams (ratio 85 : 15). Chromatography (EtOAc–hexane, 15 : 85) gave the *title compound* **12d** (76 mg, 72%) as a colourless oil;  $[a]_D^{29} - 143 \pm 7$  (*c* 3.6, CHCl<sub>3</sub>); *v*<sub>max</sub>/cm<sup>-1</sup> 3065, 2975, 2887, 1638, 1451, 1410, 1217, 940, 912, 748, 730;  $\delta_c$  (100 MHz, CDCl<sub>3</sub>) 18.3 (Me), 52.7 (7-C), 72.8 (6-C), 85.7 (4b-C), 121.7, 128.1 (two), 128.9, 129.4, 129.9, 130.0 and 131.1 (Ar*C*H), 134.9, 136.17, 136.20 and 138.5 (quaternary Ar*C*), 163.7 (8-C); *m*/*z* 266 ([M + H]+, 100%) (Found: M + H, 266.1165;  $C_{17}H_{16}O_2N$  requires 266.1176);  $R_f$  0.20 (EtOAc–hexane, 3 : 7). Further elution of the column yielded a mixed fraction (17 mg, 16%) and a fraction enriched in the minor isomer **13d** (10 mg, 10%, *ca.* 80% d.e. by <sup>1</sup> H NMR spectroscopy) as a colourless oil; *v*<sub>max</sub>/cm<sup>-1</sup> 2964, 2923, 2912, 2841, 1632, 1463, 1407, 1094, 741;  $\delta_c$ (75 MHz, CDCl3) 19.1 (Me), 52.9 (7-C), 73.7 (6-C), 85.7 (4b-C), 121.7, 128.2, 128.3, 128.9, 129.7, 129.8, 130.2 and 131.5 (Ar*C*H), 134.1, 135.9, 137.1 and 139.8 (quaternary Ar*C*), 163.6 (8-C); *m*/*z* 266 ([M + H]<sup>+</sup>, 100%) (Found: M + H, 266.1181;  $C_{17}H_{16}O_2N$ requires 266.1176); *R<sub>f</sub>* 0.14 (EtOAc–hexane, 3 : 7).

#### **(a***S***,4b***R***,7***S***)-7-Phenylmethoxymethyl-6,7-dihydrodibenz- [***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 12e and (a***R***,4b***S***,7***S***)-7 phenylmethoxymethyl-6,7-dihydrodibenz[***c***,***e***]oxazolo- [3,2-***a***]azepin-9(4b***H***)-one 13e**

**Method A.** Heating the acid-aldehyde **7** (100 mg, 0.44 mmol) and (*R*)-2-amino-3-benzyloxy-1-propanol **11e** (120 mg, 0.66 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 36 h gave the mixed lactams **12e** and **13e** (total 100 mg,  $61\%$ ), ratio  $1:1$  by <sup>1</sup>H NMR spectroscopy.

**Method B.** Heating the ester-aldehyde **9** (79 mg, 0.33 mmol) and (*R*)-2-amino-3-benzyloxy-1-propanol **11e** (89 mg, 0.49 mmol) in xylene (5 mL) at 155 *◦*C (bath temp.) for 3 d followed by removal of the solvent *in vacuo* gave a mixture of isomeric lactams (ratio 87 : 13). Chromatography (EtOAc–hexane, 15 : 85) gave the *title compound* **12e** (90 mg, 74%) as a colourless gum;  $[a]_D^{29} - 96 \pm$ 7 (*c* 4.1, CHCl<sub>3</sub>); *v*<sub>max</sub>/cm<sup>-1</sup> 3063, 2950, 2885, 1640, 1451, 1409, 1214, 1097, 920, 748, 737;  $\delta_c$  (100 MHz, CDCl<sub>3</sub>) 56.0 (7-C), 67.7  $(CH<sub>2</sub>), 69.2 (CH<sub>2</sub>), 73.5 (CH<sub>2</sub>), 86.0 (4b-C), 121.9, 127.8 (three),$ 128.1, 128.2, 128.5 (two), 129.0, 129.4, 130.0 and 130.1 (Ar*C*H), 134.5, 136.2 (two), 138.1 and 138.4 (quaternary Ar*C*), 164.2 (8- C);  $m/z$  394 ([M + Na]<sup>+</sup>, 100%), 372 ([M + H]<sup>+</sup>, 47) (Found: M + Na, 394.1421; C<sub>24</sub>H<sub>21</sub>O<sub>3</sub>NNa requires 394.1414); *R*<sub>f</sub> 0.29 (EtOAc– hexane, 3 : 7). Further elution of the column yielded a mixed fraction (28 mg, 23%, ratio **12e** : **13e** 1 : 1.6) *R*<sup>f</sup> 0.29 + 0.21 (EtOAc– hexane, 3 : 7).

### **(a***S***,4b***R***,7***S***)-7-***tert***-Butyl-6,7-dihydrodibenz[***c***,***e***]oxazolo[3,2** *a***]azepin-9(4b***H***)-one 12f and (a***R***,4b***S***,7***S***)-7-***tert***-Butyl-6,7 dihydrodibenz[***c***,***e***]oxazolo[3,2-***a***]azepin-9(4b***H***)-one 13f**

**Method A.** Heating the acid-aldehyde **7** (280 mg, 1.24 mmol) and (*S*)-*tert*-leucinol **11f** (216 mg, 1.84 mmol) in toluene (15 mL) under reflux (bath temp. 120 *◦*C) for 36 h gave the mixed lactams **12f** and **13f** (total 210 mg, 55%), ratio 64 : 36 by <sup>1</sup> H NMR spectroscopy, as a colourless gum; *v*<sub>max</sub>/cm<sup>-1</sup> 3067, 2966, 2873, 2244, 1650, 1452, 1394, 1219, 1153, 1083, 912, 741; *m*/*z* 308 ([M +  $H$ <sup>+</sup>, 100%).

**Method B.** Heating the ester-aldehyde **9** (230 mg, 0.96 mmol) and the amino alcohol **11f** (168 mg, 1.43 mmol) in xylene (15 mL) at 155 *◦*C (bath temp.) for 3 d gave no lactams by <sup>1</sup> H NMR spectroscopy.

### **Molecular mechanics calculations (Table 4, Fig. 1 and Fig. 2)**

Minimised steric energy (MSE) values for the lactams **12**, **13** (Table 4), and **16–21** (Fig. 1) were calculated on a PC running Linux (Fedora Core 3) with MacroModel v. 8.0 (Maestro v. 5.0 interface) using the MM3 force field and Monte Carlo conformational search (*csearch*) method (1000 iterations). The standard minimisation parameters were: no solvent; PRCG method; convergence on gradient; max. number of iterations 3000; convergence threshold 0.0200. The procedure returned multiple repeats of the same global MSE in each case. The difference,  $\Delta G$ , for each pair of structures 12 and 13 was converted into the equilibrium populations indicated in Table 4 using the equation  $\Delta G = -RT \ln K$  (where  $R = 8.31451 \text{ J K}^{-1} \text{ mol}^{-1}$ ). The dihedral driving (*drive*) plots shown in Fig. 2 were acquired by locating the energy-minimised structure for **16** using *csearch* as described

above, and then disconnecting the oxazolidine ring at C(4b). The identities of H(4b) and O(5) were exchanged and the oxazolidine ring was then reconnected. A constraint (force constant 100, range ±10*◦*) was imposed on the (*S*)-configured biaryl torsion angle (42.5*◦*) and the structure was subjected to a new *csearch* operation. The torsional constraint was removed from the resulting structure, *ent*-**17**, whose steric energy was then minimised (*mini*) once more. MSE values for **18–21** were calculated similarly. The structures **16** and *ent*-**17** were each subjected to a *drive* analysis of the dihedral angle  $C(1)$ – $C(13b)$ – $C(13a)$ – $C(13)$  in the region of the respective minima (interval 0.1*◦*), which provided the data for the plots in Fig. 2. The calculated MSE values (kJ mol−<sup>1</sup> ) were: **16**, 103.95; **17**, 214.47; **18**, 118.87; **19**, 118.28; **20**, 27.67; **21**, 55.44.

#### **Acid-induced equilibration of lactams (Table 5)**

Except for entry 1, all temperatures are those of oil baths and are approximate (±5 *◦*C).

**Entry 1.** A solution of the lactam **12a** (11.2 mg, 0.038 mmol) and *p*-toluenesulfonic acid hydrate (2.6 mg, 0.014 mmol) in CD<sub>3</sub>CN (6 mL) was heated at  $55 \pm 2 °C$  (bath) for a total of 33 d, during which time samples were periodically removed for analysis by <sup>1</sup> H NMR spectroscopy. The integrals for the respective H(4b) signals were used to monitor the change in the diastereoisomer ratio [**13a**]/[**12a**]. The data used to plot Fig. 3 are listed in Table 6.

**Table 6** Data used to plot Fig. 3

12a $(\%)$	Time/h	
100.0	0.0	
98.1	9.0	
96.8	15.0	
77.6	107.0	
65.2	184.5	
58.6	250.5	
46.4	419.5	
43.8	493.0	
40.2	611.0	
38.2	688.0	
36.7	758.5	
36.0	805.5	

For the equilibration of **A** and **B** *via* first-order processes, the change in concentration of **A** is related to the respective forward and reverse rate constants  $k_1$  and  $k_{-1}$  using the expression

$$
\frac{\mathrm{d}[\mathbf{A}]}{\mathrm{d}t} = -k_1[\mathbf{A}] + k_{-1}[\mathbf{B}] \tag{1}
$$

and the equilibration process is represented by the integrated rate equation, eqn (2).

$$
[\mathbf{A}]_t = [\mathbf{A}]_{\infty} + ([\mathbf{A}]_0 - [\mathbf{A}]_{\infty}) e^{-(k_1 + k_{-1})t}
$$
 (2)

The value of  $k_{-1}$  corresponds to  $k_1/K$ , where *K* is the value of [**B**]/[**A**] at equilibrium.

Fig. 3 was plotted using the observed isomer ratios listed in Table 6. The calculated exponential decay curve for [**12a**] was generated using eqn (2) with the variables [**12a**]∞, {[**12a**]0 − [**12a**]∞} and  $(k_1 + k_{-1})$  optimised by minimising the sum of the  $R^2$  values for each data point. The data yielded the following parameters (errors approximate, based on  $\pm 2\%$  accuracy in NMR integrals):  $k_1 = 7.3 \times 10^{-7} \text{ s}^{-1} (\pm 0.3 \times 10^{-7})$ 

 $k_{-1} = 3.7 \times 10^{-7} \text{ s}^{-1} (\pm 0.3 \times 10^{-7})$  $[A]_{\infty} = 34\% (\pm 2\%)$  $[\mathbf{A}]_0 - [\mathbf{A}]_\infty = 67\% (\pm 2\%)$ 

**Entry 2.** A solution of the lactam **12a** (8.2 mg, 0.028 mmol) and *p*-toluenesulfonic acid hydrate (2.0 mg, 0.011 mmol) in toluene- $d_8$ (0.6 mL) was heated in a sealed tube at 140 *◦*C for 3 d, during which time the mixture was periodically analysed by <sup>1</sup>H NMR spectroscopy. The estimated equilibrium ratio **12a** : **13a** was 27 : 73.

**Entry 3.** A solution of the lactam **12a** (11.2 mg, 0.038 mmol) in toluene- $d_8$  (0.6 mL) was heated in a sealed tube at 140  $\rm{°C}$  for 7 d, after which time the <sup>1</sup> H NMR spectrum indicated that **12a** remained intact. No other products were evident.

**Entry 4.** A sample of the lactam **12a** (20 mg, 0.07 mmol) in toluene- $d_8$  (0.5 mL) in an NMR tube was treated with a solution of TFA in toluene- $d_8$  (6.7 M, 0.1 mL, 0.67 mmol). The stoppered tube was sealed in a screw-capped thick-walled glass tube and heated at 100 °C for 7 d. The equilibration, monitored by <sup>1</sup>H NMR spectroscopy, stabilised with an estimated **12a**:**13a** ratio of 29 : 71.

**Entry 5.** A sample of the lactam **12b** (20 mg, 0.06 mmol) in toluene- $d_8$  (0.5 mL) in an NMR tube was treated with a solution of TFA in toluene- $d_8$  (6.7 M, 0.1 mL, 0.67 mmol). The stoppered tube was sealed in a screw-capped thick-walled glass tube and heated at 100 °C for 7 d. The equilibration, monitored by <sup>1</sup>H NMR spectroscopy, stabilised with an estimated **12b**:**13b** ratio of 45 : 55.

**Entry 6.** A sample of the lactam **12b** (50 mg) in xylene (10 mL) was sealed in a screw-capped thick-walled glass tube and heated at 150 *◦*C for 2 d. Evaporation of the solvent and analysis of the residue by <sup>1</sup>H NMR spectroscopy indicated that no equilibration had occurred.

**Entry 7.** A sample of the lactam **12c** (20 mg, 0.06 mmol) in toluene- $d_8$  (0.5 mL) in an NMR tube was treated with a solution of TFA in toluene- $d_8$  (6.7 M, 0.1 mL, 0.67 mmol). The stoppered tube was sealed in a screw-capped thick-walled glass tube and heated at 100 °C for 7 d. The equilibration, monitored by <sup>1</sup>H NMR spectroscopy, stabilised with an estimated **12c**:**13c** ratio of 36 : 64.

**Entry 8.** A sample of the lactam **12c** (20 mg, 0.06 mmol) in formic acid (4 mL) was sealed in a screw-capped thick-walled glass tube and heated at 100 *◦*C for 3 d. Evaporation of the solvent and analysis of the residue by <sup>1</sup> H NMR spectroscopy gave an estimated **12c**:**13c** ratio of 43 : 57.

**Entry 9.** A mixture of the lactams **12d** and **13d** (ratio *ca.* 56 : 44; 20 mg, 0.075 mmol) in toluene- $d_8$  (0.5 mL) in an NMR tube was treated with a solution of TFA in toluene- $d_8$  (6.7 M, 0.1 mL, 0.67 mmol). The stoppered tube was sealed in a screwcapped thick-walled glass tube and heated at 100 *◦*C for 7 d. The equilibration, monitored by <sup>1</sup>H NMR spectroscopy, stabilised with an estimated **12d**:**13d** ratio of 34 : 66.

**Entry 10.** A mixture of the lactams **12e** and **13e** (ratio *ca.* 50 : 50; 50 mg, 0.16 mmol) and TFA (0.2 mL, 2.7 mmol) in xylene (10 mL) was sealed in a screw-capped thick-walled glass tube and

heated at 150 °C for 3 d. The equilibration, monitored by <sup>1</sup>HNMR spectroscopy, stabilised with an estimated **12e**:**13e** ratio of 30 : 70.

**Entry 11.** A mixture of the lactams **12f** and **13f** (ratio *ca.* 64 : 36; 20 mg, 0.065 mmol) in toluene- $d_8$  (0.5 mL) in an NMR tube was treated with a solution of TFA in toluene- $d_8$  (6.7 M, 0.1 mL, 0.67 mmol). The stoppered tube was sealed in a screwcapped thick-walled glass tube and heated at 100 *◦*C for 7 d. The equilibration, monitored by <sup>1</sup>H NMR spectroscopy, stabilised with an estimated **12f**:**13f** ratio of 26 : 74.

#### **Acknowledgements**

We are grateful to the Association for International Cancer Research, the EPSRC and GlaxoSmithKline for their financial support of this work. We also thank Val Boote and Steve Kelly for assistance with MS and NMR measurements, and Drs Andrew Regan and Ian Watt for valuable discussions. We also wish to acknowledge the use of the EPSRC's Chemical Database Service at Daresbury.**<sup>32</sup>**

#### **References**

- 1 Reviews: (*a*) T. W. Wallace, *Org. Biomol. Chem.*, 2006, **4**, 3197–3210; (*b*) G. Bringmann, A. J. Price Mortimer, P. A. Keller, M. J. Gresser, J. Garner and M. Breuning, *Angew. Chem., Int. Ed.*, 2005, **44**, 5384–5427.
- 2 A. I. Meyers and J. J. Willemsen, *Chem. Commun.*, 1997, 1573–1574 and references cited therein.
- 3 A. Brossi, *J. Med. Chem.*, 1990, **33**, 2311–2319. See also: U. Berg and H. Bladh, *Helv. Chim. Acta*, 1999, **82**, 323–325.
- 4 A. Brossi, O. Boye, A. Muzaffar, H. J. C. Yeh, V. Toome, B. Wegrzynski ´ and C. George, *FEBS Lett.*, 1990, **262**, 5–7.
- 5 For examples, see: K. Mikami, K. Aikawa, Y. Yusa, J. J. Jodry and M. Yamanaka, *Synlett*, 2002, 1561–1578; A. Alexakis and C. Benhaim, *Eur. J. Org. Chem.*, 2002, 3221–3236; T. Ooi, Y. Uematsu, M. Kameda and K.Maruoka, *Angew. Chem., Int. Ed.*, 2002, **41**, 1551–1554; B. Lygo, B. Allbutt and S. R. James, *Tetrahedron Lett.*, 2003, **44**, 5629–5632; K. Morioka, N. Tamagawa, K. Maeda and E. Yashima, *Chem. Lett.*, 2006, **35**, 110–111.
- 6 D. J. Edwards, R. G. Pritchard and T. W. Wallace, *Acta Crystallogr., Sect. B: Struct. Sci.*, 2005, **61**, 335–345.
- 7 Z. Zhang, H. Qian, J. Longmire and X. Zhang, *J. Org. Chem.*, 2000, **65**, 6223–6226.
- 8 D. Romo and A. I. Meyers, *Tetrahedron*, 1991, **47**, 9503–9569; M. D. Groaning and A. I. Meyers, *Tetrahedron*, 2000, **56**, 9843–9873.
- 9 D. J. Edwards, R. G. Pritchard and T. W. Wallace, *Tetrahedron Lett.*, 2003, **44**, 4665–4668.
- 10 Y. Kubo, T. Araki and K. Maruyama, *Bull. Chem. Soc. Jpn.*, 1985, **58**, 2863–2869.
- 11 L. Giraud, E. Lacôte and P. Renaud, *Helv. Chim. Acta*, 1997, 80, 2148– 2156.
- 12 M. Penhoat, V. Levacher and G. Dupas, *J. Org. Chem.*, 2003, **68**, 9517– 9520.
- 13 M. Penhoat, S. Leleu, G. Dupas, C. Papamicaël, F. Marsais and V. Levacher, *Tetrahedron Lett.*, 2005, **46**, 8385–8389.
- 14 R. A. Labriola and A. Felitte, *J. Org. Chem.*, 1943, **8**, 536–539.
- 15 E. F. M. Stephenson, *J. Chem. Soc.*, 1954, 2354–2357.
- 16 P. S. Bailey and R. E. Erickson, *Org. Synth.*, 1973, coll. vol. 5, pp. 493–495.
- 17 K. Schlögl and R. Schölm, Monatsh. Chem., 1980, 111, 259-274.
- 18 K. Schlögl and R. Schölm, *Liebigs Ann. Chem.*, 1980, 1877–1888.
- 19 A. J. Mancuso and D. Swern, *Synthesis*, 1981, 165–185.
- 20 H. Kalchhauser, K. Schlögl, W. Weissensteiner and A. Werner, J. Chem. *Soc., Perkin Trans. 1*, 1983, 1723–1729.
- 21 The rotation barrier in formamide has been estimated at 72 kJ mol−<sup>1</sup> using *ab initio* methods. E. D. Glendening and J. A. Hrabal, *J. Am. Chem. Soc.*, 1997, **119**, 12940–12946. See also: X. Lopez, J. I. Mujika, G. M. Blackburn and M. Karplus, *J. Phys. Chem. A*, 2003, **107**, 2304– 2315.
- 22 K. Higashiyama, H. Inoue and H. Takahashi, *Tetrahedron Lett.*, 1992, **33**, 235–238.
- 23 W. Ando, Y. Igarashi and L. Huang, *Chem. Lett.*, 1987, 1361–1364. See also: D. Seebach and J. D. Aebi, *Tetrahedron Lett.*, 1984, **25**, 2545–2548.
- 24 M. Amat, N. Llor and J. Bosch, *Tetrahedron Lett.*, 1994, **35**, 2223– 2226; M. Amat, J. Bosch, J. Hidalgo, M. Cantó, M. Pérez, N. Llor, E. Molins, C. Miravitlles, M. Orozco and J. Luque, *J. Org. Chem.*, 2000, **65**, 3074–3084.
- 25 P. Pigeon and B. Decroix, *Tetrahedron Lett.*, 1997, **38**, 1041–1042.
- 26 G. Hilt, F. Galbiati and K. Harms, *Synthesis*, 2006, 3575–3584.
- 27 M. Tichy, M. Budesinsky, J. Günterova, J. Zavada, J. Podlaha and I. Cisarova, *Tetrahedron*, 1999, **55**, 7893–7906.
- 28 D. D. Perrin, W. L. F. Armarego and D. R. Perrin, *Purification of Laboratory Chemicals*, Pergamon, Oxford, 2nd edn, 1980.
- 29 W. C. Still, M. Kahn and A. Mitra, *J. Org. Chem.*, 1978, **43**, 2923–2925.
- 30 V. Brandmeier and M. Feigel, *Tetrahedron*, 1989, **45**, 1365–1376.
- 31 J. M. Schomaker, B. R. Travis and B. Borhan, *Org. Lett.*, 2003, **5**, 3089–3092.
- 32 D. A. Fletcher, R. F. McMeeking and D. Parkin, *J. Chem. Inf. Comput. Sci.*, 1996, **36**, 746–749.